Review top news and interview highlights from the week ending November 10, 2023.
Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
The therapy was previously granted priority review in May 2023.
The medical oncologist at Moffitt Cancer Center discussed 3 different approaches to cell therapy that could lead to new treatment options in the field.
Among 20 patients who received MDR-101, 12 have completed participation in the trial and have not taken their immunosuppression therapy for 2 years.
The chief scientific officer of CureDuchenne discussed research he is looking forward to seeing in 2024.
Microsatellite instability (MSI) tumors are frequently found in people with Lynch syndrome, one of the most common hereditary colorectal cancers.